155 related articles for article (PubMed ID: 31099631)
81. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
82. The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
[TBL] [Abstract][Full Text] [Related]
83. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
84. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS; Burger RA; Enserro D; Norquist BM; Swisher EM; Brady MF; Bookman MA; Fleming GF; Huang H; Homesley HD; Fowler JM; Greer BE; Boente M; Liang SX; Ye C; Bais C; Randall LM; Chan JK; Ferriss JS; Coleman RL; Aghajanian C; Herzog TJ; DiSaia PJ; Copeland LJ; Mannel RS; Birrer MJ; Monk BJ
J Clin Oncol; 2019 Sep; 37(26):2317-2328. PubMed ID: 31216226
[TBL] [Abstract][Full Text] [Related]
85. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
86. Biomarkers in ovarian cancer: To be or not to be.
Arend R; Martinez A; Szul T; Birrer MJ
Cancer; 2019 Dec; 125 Suppl 24():4563-4572. PubMed ID: 31967683
[TBL] [Abstract][Full Text] [Related]
87. Treatment of recurrent epithelial ovarian cancer.
Pignata S; Pisano C; Di Napoli M; Cecere SC; Tambaro R; Attademo L
Cancer; 2019 Dec; 125 Suppl 24():4609-4615. PubMed ID: 31967680
[TBL] [Abstract][Full Text] [Related]
88. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN
J Clin Oncol; 2020 Oct; 38(30):3528-3537. PubMed ID: 32749942
[TBL] [Abstract][Full Text] [Related]
89. Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
DiSilvestro P; Colombo N; Harter P; González-Martín A; Ray-Coquard I; Coleman RL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830911
[TBL] [Abstract][Full Text] [Related]
90. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R
J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344
[TBL] [Abstract][Full Text] [Related]
91. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
92. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
93. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
[TBL] [Abstract][Full Text] [Related]
94. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
Hu W; Li M; Chen Y; Gu X
J Ovarian Res; 2021 Sep; 14(1):121. PubMed ID: 34535173
[TBL] [Abstract][Full Text] [Related]
95. First-line PARP inhibitors in ovarian cancer: summary of an
Banerjee S; Gonzalez-Martin A; Harter P; Lorusso D; Moore KN; Oaknin A; Ray-Coquard I
ESMO Open; 2020 Nov; 5(6):e001110. PubMed ID: 33310779
[TBL] [Abstract][Full Text] [Related]
96. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
Wu L; Zhu J; Yin R; Wu X; Lou G; Wang J; Gao Y; Kong B; Lu X; Zhou Q; Wang Y; Chen Y; Lu W; Li W; Cheng Y; Liu J; Ma X; Zhang J
Gynecol Oncol; 2021 Jan; 160(1):175-181. PubMed ID: 33250205
[TBL] [Abstract][Full Text] [Related]
97. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
98. Latest clinical evidence of maintenance therapy in ovarian cancer.
Walsh CS
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):15-21. PubMed ID: 31833941
[TBL] [Abstract][Full Text] [Related]
99. New Therapies for Ovarian Cancer.
O'Malley DM
J Natl Compr Canc Netw; 2019 May; 17(5.5):619-621. PubMed ID: 31117037
[TBL] [Abstract][Full Text] [Related]
100. Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer.
Escalona RM; Chu S; Kadife E; Kelly JK; Kannourakis G; Findlay JK; Ahmed N
Cancer Cell Int; 2022 Dec; 22(1):422. PubMed ID: 36585738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]